Clinical Trials Logo

Clinical Trial Summary

phase 2 study. Target disease: Crohn's disease.

Rational and relevance to IBD patients:

Copaxone is known for its high safety profile and for acting as an effective immunomodulatory agent for the treatment of MS. . In experimental models of IBD, a beneficial effect of Copaxone was demonstrated where significant amelioration of macroscopic colonic damage, preservation of the microscopic colonic structure, reduced weight loss, and improved long-term survival in treated compared with untreated mice was demonstrated. In addition, Copaxone suppressed the proliferation of local mesenteric lymphocytes to syngeneic colon extract, significantly reduced the overall secretion of TNF-α and induced the secretion of transforming growth factor (TGF)-β. The ability of Copaxone to effectively modulate the clinical manifestations and the detrimental immune response involved in experimental colitis, together with its high safety profile support its potential effect as a new treatment for CD.

Patients: patients with moderately active Crohn's disease as indicated by a CDAI 220 - 450, whose diagnosis was done more than 3 months before enrollment.

Study objectives: to test the efficacy and safety of Copaxone in CD patients.

Study design: This will be a single center, randomized, double blind placebo controlled phase 2 study.

Subjects will be assessed for study eligibility 1 to 2 weeks prior to baseline Eligible patients will be enrolled into the study after signing an informed consent form and allocated in a 1.5:1 ratio to receive either Copaxone or placebo. A total of 50 patients will be recruited.

Subcutaneous injections (Copaxone or Placebo) will be administered daily through week 12. Patient assessment of safety and efficacy will be made at weeks 0,4,8,12 and 16.

At week 12 non-responders would be offered an open label arm with daily Copaxone 20mg for the next 12 weeks


Clinical Trial Description

Data evaluation: Evidence of therapeutic benefit and safety will be evaluated by the following assessments:

Clinical assessments:

- Crohn's disease activity will be assessed by components of the CDAI.

- Mucosal healing will be assessed by VCE (data will be quantitated using the Lewis score). Patients requiring colonoscopy according to Physicians decision would also be offered to participate in an endoscopic mucosal healing evaluation substudy. Patients participating will undergo colonoscopy and biopsies at the beginning (screening±1 week) and the end (week 12±1 week) of the treatment period. Endoscopic damage will be assessed using the CDEIS

- Mean (median) doses of corticosteroids and the average total aggregate dose of corticosteroids received per patient during the trial will be assessed.

- Quality of life will be assessed by components of the Inflammatory Bowel Disease Questionnaire(IBDQ).

Safety:

- AE incidence

- Physical examination

- Clinical laboratory values

- Vital signs

Tolerability and Safety:

- Adverse events, dropout rate will be registered.

- Proportion of subjects who prematurely discontinue the study.

- Proportion of subjects who prematurely discontinue the study due to Aes

- Time to premature discontinuation

- Time to premature discontinuation due to Aes.

Immunologic assessment (including lymphocyte proliferation and cytokine secretion assays) will be performed at the baseline visit as well as weeks 4 and 12 and 16. Serum samples for cytokine studies 24 hours after first injection would also be collected. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00731172
Study type Interventional
Source Tel-Aviv Sourasky Medical Center
Contact Iris Dotan, MD
Phone 972-3-6947305
Email irisd@tasmc.health.gov.il
Status Recruiting
Phase Phase 2
Start date September 2008
Completion date July 2011

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04989907 - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Active, not recruiting NCT00132184 - Vitamin D Treatment for Crohn´s Disease Phase 2/Phase 3
Active, not recruiting NCT02476643 - Integrative Gastroenterology - an Observational Trial
Terminated NCT01203254 - Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease Phase 4
Completed NCT00454545 - Atorvastatin in Moderate Active Crohns Disease Phase 2
Completed NCT01593462 - Comparative Effectiveness of MR Enterography N/A
Completed NCT01769755 - A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease Phase 1
Terminated NCT01582568 - EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment Phase 4
Active, not recruiting NCT04397263 - A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease Phase 3
Completed NCT01947010 - Pneumococcal Vaccination of Crohn Patients Phase 4
Terminated NCT00946361 - Impaired Insulin-like Growth Factor-1 (IGF-1) Generation Causes Protein Catabolism and Poor Growth in Children With Crohn Disease N/A
Completed NCT00940576 - Dietetic Efficacy of Mare's Milk for Patients With Chronic Inflammatory Bowel Diseases N/A
Completed NCT03981939 - Perianal Fistula (PAF) Validation and Burden of Illness Study
Recruiting NCT05452304 - AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's Disease Phase 1
Completed NCT04885920 - A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)
Recruiting NCT02130349 - IBDSL Biobank Project. Molecular Markers for Diagnosis and Therapy Response in IBD. N/A
Completed NCT01145365 - Study to Look at Benefit of Surgical Drainage Before Beginning Medical Therapy for Crohns Perianal Fistulas N/A
Completed NCT00774982 - Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients Phase 1
Active, not recruiting NCT04959851 - A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium)
Active, not recruiting NCT04940611 - A Study of Surgical Interventions in Fistulizing Conditions